Legal & General Group Plc Has $319.38 Million Stake in Edwards Lifesciences Corporation $EW

Legal & General Group Plc reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 2.8% in the 3rd quarter, Holdings Channel reports. The fund owned 4,106,769 shares of the medical research company’s stock after selling 117,123 shares during the quarter. Legal & General Group Plc’s holdings in Edwards Lifesciences were worth $319,383,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of EW. True Wealth Design LLC grew its position in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. Rakuten Securities Inc. raised its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the period. Hantz Financial Services Inc. lifted its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in Edwards Lifesciences in the third quarter valued at approximately $30,000. Finally, Strengthening Families & Communities LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $34,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on EW shares. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Citigroup reiterated a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $90.00 to $100.00 in a report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the sale, the vice president owned 33,934 shares in the company, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 74,123 shares of company stock worth $6,275,599 in the last three months. Insiders own 1.29% of the company’s stock.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Brokerage consensus remains constructive — Edwards has an average rating of “Moderate Buy,” which supports longer-term investor demand and suggests analysts see upside vs. current valuation. Article Title
• Positive Sentiment: Equity research and trade ideas continue to include EW among attractive medical-instruments names, citing product pipeline, secular TAVR/TMV growth and margin upside — a positive for investor interest and potential inflows. Article Title
• Neutral Sentiment: Management presented at recent healthcare conferences (Barclays and Leerink); transcripts are available for investors to assess guidance, R&D and commercial cadence but contained no market-moving surprises in summary. These presentations can influence sentiment depending on Q&A details. Barclays Transcript Leerink Transcript
• Negative Sentiment: Significant insider selling by senior finance staff: CFO Scott Ullem sold 13,000 shares (a ~24.7% reduction in his holding) at ~$84.92 — a sizeable, public reduction by the company’s finance chief can alarm investors about near-term conviction. SEC Filing
• Negative Sentiment: Additional insider sale: VP Daniel Lippis sold 1,019 shares at ~$85.38. Though smaller, combined insider selling activity increases pressure on sentiment. SEC Filing
• Negative Sentiment: Short interest jumped sharply in February (up ~56.6% to ~12.38M shares, ~2.1% of shares outstanding), suggesting increased bearish bets that can amplify downward moves and volatility on negative headlines. (No link provided)

Edwards Lifesciences Price Performance

NYSE EW opened at $85.08 on Thursday. The firm’s 50 day moving average is $82.49 and its 200-day moving average is $81.55. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $49.42 billion, a PE ratio of 46.49, a price-to-earnings-growth ratio of 2.24 and a beta of 0.93. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.